IGC (IGC Pharma) Total Receivables: $0.10 Mil (As of Mar. 2026)


IGC IGC Pharma Inc IGC
29 GF Score
Price $0.26
GF Value $0.24
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Total Receivables?

IGC Pharma IGC -0.42% 29 Total Receivables is $0.10 Mil as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Fairly Valued). The stock has 6 warning signs investors should review.

IGC Pharma's Total Receivables for the quarter that ended in Mar. 2026 was $0.10 Mil.

IGC Pharma Total Receivables Historical Data

* Premium members only.

The historical data trend for IGC Pharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Total Receivables Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.92 0.60 0.13 0.09 0.08

IGC Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.19 0.06 0.08 0.10
IGC
29GF Score
IGC Pharma Inc IGC
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.10 Mil mean?
IGC Pharma (IGC) has a Total Receivables of $0.10 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on IGC Pharma and its competitors.
Is IGC Pharma's Total Receivables too high?
IGC Pharma's current Total Receivables is $0.10 Mil. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Total Receivables compare to SER and NRSN?
IGC Pharma's Total Receivables of $0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on IGC Pharma and its competitors. IGC Pharma's current Total Receivables is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Fairly Valued. The stock's GF Value™ is $0.24, compared to a current price of $0.26 — trading 9.1% above its estimated fair value. The current Total Receivables is $0.10 Mil. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For IGC Pharma (IGC), the current Total Receivables is $0.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.26 is trading 9.1% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Fairly Valued.

Key valuation signals for IGC:

  • Total Receivables: $0.10 Mil
  • GF Value™: $0.24 vs. price of $0.26 (9.1% above fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score

Get the complete analysis for IGC

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price
$0.24
GF Value